ClinVar Miner

Submissions for variant NM_000487.6(ARSA):c.465+1G>A (rs80338815)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 12
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
EGL Genetic Diagnostics,Eurofins Clinical Diagnostics RCV000335617 SCV000110808 pathogenic not provided 2015-08-06 criteria provided, single submitter clinical testing
GeneDx RCV000335617 SCV000329083 pathogenic not provided 2018-08-29 criteria provided, single submitter clinical testing The c.465+1G>A variant is a common pathogenic variant in central and western European populations associated with metachromatic leukodystrophy (MLD) with no functional arylsulfatase A activity and designated as an I-type (Infantile/juvenile-onset) ARSA allele (Polten et al., 1991; Biffi et al., 2008; Gomez-Ospina, 2017). The c.465+1G>A variant destroys the canonical splice donor site in intron 2, and is expected to cause abnormal gene splicing, either leading to an abnormal message that is subject to nonsense-mediated mRNA decay, or to an abnormal protein product if the message is used for protein translation. We interpret c.465+1G>A as a pathogenic variant.
Center for Pediatric Genomic Medicine,Children's Mercy Hospital and Clinics RCV000335617 SCV000610089 pathogenic not provided 2017-04-24 criteria provided, single submitter clinical testing
Invitae RCV000020319 SCV000627142 pathogenic Metachromatic leukodystrophy 2018-12-19 criteria provided, single submitter clinical testing This sequence change affects a donor splice site in intron 2 of the ARSA gene. It is expected to disrupt RNA splicing and likely results in an absent or disrupted protein product. This variant is present in population databases (rs80338815, ExAC 0.1%). This variant has been reported in the literature in individuals affected with metachromatic leukodystrophy (PMID: 1670590, 18786133, 21167507, 26462614, 9090526, 11456299, 9600244, 7825603). This variant is also known in the literature as c.459+1G>A, IVS2+1G>A, and allele I or 0. ClinVar contains an entry for this variant (Variation ID: 3051). Donor and acceptor splice site variants typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in ARSA are known to be pathogenic (PMID: 8962139, 10477432). For these reasons, this variant has been classified as Pathogenic.
Counsyl RCV000020319 SCV000677978 pathogenic Metachromatic leukodystrophy 2015-06-14 criteria provided, single submitter clinical testing
Integrated Genetics/Laboratory Corporation of America RCV000020319 SCV000696808 pathogenic Metachromatic leukodystrophy 2017-05-21 criteria provided, single submitter clinical testing Variant summary: The ARSA c.465+1G>A variant involves the alteration of a conserved intronic nucleotide and 5/5 splice prediction tools predict a significant impact on normal splicing, which has been functionally supported (Zlotogora_1994 and Polten_1991). This variant was found in 88/111568 control chromosomes at a frequency of 0.0007888, which does not exceed the estimated maximal expected allele frequency of a pathogenic ARSA variant (0.0027951). Multiple publications have cited the variant in homozygous and compound heterozygous affected individuals diagnosed with late-, juvenile- and adult-onset depending on the second mutation in trans. The variant of interest has been indicated to be a common founder mutation (Zlotogora_1994 and Polten_1991). In addition, multiple clinical diagnostic laboratories/reputable databases classified this variant as pathogenic. Taken together, this variant is classified as pathogenic.
Fulgent Genetics,Fulgent Genetics RCV000020319 SCV000893600 pathogenic Metachromatic leukodystrophy 2018-10-31 criteria provided, single submitter clinical testing
Illumina Clinical Services Laboratory,Illumina RCV000020319 SCV000915006 pathogenic Metachromatic leukodystrophy 2018-12-18 criteria provided, single submitter clinical testing The ARSA c.465+1G>A variant, also referred to as c.459+1G>A, has been described as one of the most common pathogenic variants for arylsulfatase A deficiency occurring in the central and western European populations (Fluharty et al. 2006). Across a selection of the available literature, the c.465+1G>A variant has been identified in at least eight homozygotes, 16 compound heterozygotes, and 25 heterozygotes with an uncharacterized second allele, giving an allele frequency ranging from 7.5% to 37% in patients with arylsulfatase A deficiency (Polten et al. 1991; Eto et al. 1993; Draghia et al. 1997; Berger et al. 1997; Lugowska et al. 2005; Biffi et al. 2008; Shukla et al. 2011). Biochemical analyses indicate that the variant is associated with no residual arylsulfatase A activity (Polten et al. 1991). The c.465+1G>A variant is reported at a frequency of 0.00132 in the European (non-Finnish) population of the Exome Aggregation Consortium. Based on the collective evidence, the c.465+1G>A variant is classified as pathogenic for arylsufatase A deficiency. This variant was observed by ICSL as part of a predisposition screen in an ostensibly healthy population.
OMIM RCV000003192 SCV000023350 pathogenic Metachromatic leukodystrophy, juvenile type 2001-07-01 no assertion criteria provided literature only
OMIM RCV000003194 SCV000023352 pathogenic Metachromatic leukodystrophy, adult type 2001-07-01 no assertion criteria provided literature only
GeneReviews RCV000020319 SCV000040694 pathologic Metachromatic leukodystrophy 2011-08-25 no assertion criteria provided curation Converted during submission to Pathogenic.
Mayo Clinic Genetic Testing Laboratories,Mayo Clinic RCV000335617 SCV000801471 pathogenic not provided 2018-02-07 no assertion criteria provided clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.